Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Li Luo,1,* Ting Du,1,* Jiumeng Zhang,1 Wei Zhao,2 Hao Cheng,1 Yuping Yang,1 Yujiao Wu,1 Chunmei Wang,1 Ke Men,1 Maling Gou1 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, 2Department of Thoracic Onco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luo L, Du T, Zhang J, Zhao W, Cheng H, Yang Y, Wu Y, Wang C, Men K, Gou M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Human survivin T34A Heparin-polyethyleneimine nanoparticles Gene therapy Ovarian cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fcc138b8e99645f7a663360aecbc855c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fcc138b8e99645f7a663360aecbc855c
record_format	dspace
spelling	oai:doaj.org-article:fcc138b8e99645f7a663360aecbc855c2021-12-02T02:42:32ZEfficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene1178-2013https://doaj.org/article/fcc138b8e99645f7a663360aecbc855c2016-02-01T00:00:00Zhttps://www.dovepress.com/efficient-inhibition-of-ovarian-cancer-by-degradable-nanoparticle-deli-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Li Luo,1,* Ting Du,1,* Jiumeng Zhang,1 Wei Zhao,2 Hao Cheng,1 Yuping Yang,1 Yujiao Wu,1 Chunmei Wang,1 Ke Men,1 Maling Gou1 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, 2Department of Thoracic Oncology, Cancer Center, West China Hospital, Medical School, Sichuan University, Chengdu, People’s Republic of China *These authors contributed equally to this work Abstract: Gene therapy has promising applications in ovarian cancer therapy. Blocking the function of the survivin protein could lead to the growth inhibition of cancer cells. Herein, we used degradable heparin–polyethyleneimine (HPEI) nanoparticles to deliver a dominant-negative human survivin T34A (hs-T34A) gene to treat ovarian cancer. HPEI nanoparticles were characterized and were found to have a dynamic diameter of 66±4.5 nm and a zeta potential of 27.1±1.87 mV. The constructed hs-T34A gene expression plasmid could be effectively delivered into SKOV3 ovarian carcinoma cells by HPEI nanoparticles with low cytotoxicity. Intraperitoneal administration of HPEI/hs-T34A complexes could markedly inhibit tumor growth in a mouse xenograft model of SKOV3 human ovarian cancer. Moreover, according to our results, apparent apoptosis of cancer cells was observed both in vitro and in vivo. Taken together, the prepared HPEI/hs-T34A formulation showed potential applications in ovarian cancer gene therapy. Keywords: human survivin T34A, heparin–polyethyleneimine nanoparticles, gene therapy, ovarian cancerLuo LDu TZhang JZhao WCheng HYang YWu YWang CMen KGou MDove Medical PressarticleHuman survivin T34AHeparin-polyethyleneimine nanoparticlesGene therapyOvarian cancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss Issue 1, Pp 501-513 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Human survivin T34A Heparin-polyethyleneimine nanoparticles Gene therapy Ovarian cancer Medicine (General) R5-920
spellingShingle	Human survivin T34A Heparin-polyethyleneimine nanoparticles Gene therapy Ovarian cancer Medicine (General) R5-920 Luo L Du T Zhang J Zhao W Cheng H Yang Y Wu Y Wang C Men K Gou M Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
description	Li Luo,1,* Ting Du,1,* Jiumeng Zhang,1 Wei Zhao,2 Hao Cheng,1 Yuping Yang,1 Yujiao Wu,1 Chunmei Wang,1 Ke Men,1 Maling Gou1 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, 2Department of Thoracic Oncology, Cancer Center, West China Hospital, Medical School, Sichuan University, Chengdu, People’s Republic of China *These authors contributed equally to this work Abstract: Gene therapy has promising applications in ovarian cancer therapy. Blocking the function of the survivin protein could lead to the growth inhibition of cancer cells. Herein, we used degradable heparin–polyethyleneimine (HPEI) nanoparticles to deliver a dominant-negative human survivin T34A (hs-T34A) gene to treat ovarian cancer. HPEI nanoparticles were characterized and were found to have a dynamic diameter of 66±4.5 nm and a zeta potential of 27.1±1.87 mV. The constructed hs-T34A gene expression plasmid could be effectively delivered into SKOV3 ovarian carcinoma cells by HPEI nanoparticles with low cytotoxicity. Intraperitoneal administration of HPEI/hs-T34A complexes could markedly inhibit tumor growth in a mouse xenograft model of SKOV3 human ovarian cancer. Moreover, according to our results, apparent apoptosis of cancer cells was observed both in vitro and in vivo. Taken together, the prepared HPEI/hs-T34A formulation showed potential applications in ovarian cancer gene therapy. Keywords: human survivin T34A, heparin–polyethyleneimine nanoparticles, gene therapy, ovarian cancer
format	article
author	Luo L Du T Zhang J Zhao W Cheng H Yang Y Wu Y Wang C Men K Gou M
author_facet	Luo L Du T Zhang J Zhao W Cheng H Yang Y Wu Y Wang C Men K Gou M
author_sort	Luo L
title	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
title_short	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
title_full	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
title_fullStr	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
title_full_unstemmed	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
title_sort	efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin t34a gene
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/fcc138b8e99645f7a663360aecbc855c
work_keys_str_mv	AT luol efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT dut efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT zhangj efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT zhaow efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT chengh efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT yangy efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT wuy efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT wangc efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT menk efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene AT goum efficientinhibitionofovariancancerbydegradablenanoparticledeliveredsurvivint34agene
_version_	1718402262055780352

Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Ejemplares similares